



Figure 1



2/4

Figure 2

Change in CTX-II Concentrations at Weeks 12 and 24[†]




[†]LOCF Adjusted means *** Statistically significant at the $p=0.001$ level, adalimumab vs. placebo

3/4

Figure 3


Change in MMP3 Concentrations at Weeks 12 and 24[†]



[†]LOCF Adjusted means

*** Statistically significant at the $p=0.001$ level, adalimumab vs. placebo

Figure 4



[†] LOCF ***Statistically significant at $p=0.001$ level. p -value for difference between therapies from ANCOVA